Lupin had launched Fortamet, a diabetic drug, at risk in the US, causing an injunction against the drug. The company had not checked with the company which holds the patent or the regulators.
Chief Financial Officer S Ramesh clarified that Fortamet generic was launched only for few days. "There is no timeline for resolution of legislation on Fortamet generic," he added. Here is the edited transcript of his interview to CNBC-TV18. Also watch the accompanying video. Q: What would you lose by way of sales? If the case is lost, what's the potential loss?
A: We would lose an opportunity. We expected to get about USD 50-60 million in terms of sales on the particular product. This has caused an injunction, which doesn
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
